bimiralisib   

GtoPdb Ligand ID: 8383

Synonyms: PQR-309 | PQR309
Compound class: Synthetic organic
Comment: Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent (see AACR poster #2664, 2015).
The discovery of PQR309 is claimed in patent WO-2010052569-A2, where it is compound 54 (in structure tables) and Example P11 [1].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 102.52
Molecular weight 411.16
XLogP 1.83
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES Nc1ncc(c(c1)C(F)(F)F)c1nc(nc(n1)N1CCOCC1)N1CCOCC1
Isomeric SMILES Nc1ncc(c(c1)C(F)(F)F)c1nc(nc(n1)N1CCOCC1)N1CCOCC1
InChI InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)
InChI Key ADGGYDAFIHSYFI-UHFFFAOYSA-N
References
1. Cmiljanovic V, Cmiljanovic N, Giese B, Wymann M. (2010)
Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes.
Patent number: WO2010052569 A2. Assignee: University Of Basel.. Priority date: 10/11/2008. Publication date: 14/05/2010.